恶性脑胶质瘤组织MGMT的表达及临床意义

Expression of MGMT in malignant glioma tissues and its clinical meaning

目的探讨恶性脑胶质瘤组织O6-甲基鸟嘌呤-DNA甲基转移酶(MGMT)的表达与临床意义。方法选取2012年11月至2014年4月收治的166例恶性脑胶质瘤患者为研究对象,分为>50岁组86例,≤50岁组80例,采用免疫组化技术检测所有肿瘤组织MGMT蛋白表达情况。比较不同年龄患者MGMT蛋白表达情况及MGMT表达水平与患者生存时间的相关性。结果166例中,MGMT阴性表达82例,弱阳性表达40例,强阳性表达42例;MGMT阴性表达、弱阳性表达、强阳性表达患者生存时间分别为(24.15±3.27)、(17.35±3.16)、(13.25±1.34)个月,两两比较差异具有统计学意义(P<0.05)。结论恶性脑胶质瘤组织MGMT表达水平与患者预后存在一定相关性,MGMT表达水平越高,患者预后越差。

Objective To investigate the expression of 06-methyl guanine-DNA methyltransferase （MGMT） in malignant gliomas and its clinical meaning. Methods The MGMT protein expression was determined by immunohistochemiscal technique in 166 specimens of malignant gliomas tissues derived from 166 patients treated in our hospital from November, 2012 to April, 2014. The relationship between the MGMT protein expression level with patients＇ age and survival time was analyzed. Results The survival time [（24.15±3.27） months] was significantly longer in MGMT negative expression group than that [（17.35±3.16） months] in MGMT positive expression group （P〈0.01）, which was significantly longer than that [（13.25±1.34） months] in MGMT strongly positive expression group （P〈0.01）. Conclusions The expression level of MGMT in the malignant gliomas tissues is correlated with the patients＇ prognoses. High expression level of MGMT in the malignant gliomas tissues suggests bad prognosis in the patients with malignant gliomas.